cyc 682 has been researched along with quizartinib in 1 studies
| Studies (cyc 682) | Trials (cyc 682) | Recent Studies (post-2010) (cyc 682) | Studies (quizartinib) | Trials (quizartinib) | Recent Studies (post-2010) (quizartinib) |
|---|---|---|---|---|---|
| 30 | 5 | 18 | 181 | 17 | 172 |
| Protein | Taxonomy | cyc 682 (IC50) | quizartinib (IC50) |
|---|---|---|---|
| Platelet-derived growth factor receptor alpha | Homo sapiens (human) | 0.042 | |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | 4.9 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.43 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 0.1024 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lancet, JE | 1 |
1 review(s) available for cyc 682 and quizartinib
| Article | Year |
|---|---|
New agents: great expectations not realized.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Benzothiazoles; Cytosine; Gemtuzumab; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Naphthyridines; Phenylurea Compounds; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Staurosporine; Survival Analysis; Thiazoles; Treatment Failure; Vorinostat | 2013 |